HanchorBio Inc.
1.12.2023 13:03:40 CET | ACCESS Newswire | Press release
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.
Title: An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio
Location: Palexpo, Geneva, Switzerland
Presentation Number: #10951
Date and Time: Thursday, 7 December 2023 at 12:00-13:00 CET
Highlights from the Preclinical Data-
Key findings from the preclinical studies of HCB101 targeting the SIRPa- CD47 pathway include:
- HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells;
- HCB101 consistently showed excellent efficacy against hematological and solid malignancies in 14 human tumor xenograft models;
- Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression inside the tumor compared to other competing molecules, suggesting a unique MOA underlying HCB101's superior efficacy;
- No adverse reaction was observed in cynomolgus monkey toxicology studies, indicating a good safety profile;
- HCB101 is currently being evaluated in a multi-regional, multi-center clinical study (NCT05892718) in the United States and Taiwan.
About HCB101
Discovered through structure-guided protein design which was further supplemented with relevant screening technologies, HCB101 is an engineered extracellular IgV domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of macrophages by blocking the "do not eat" signal between macrophages and the tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a much safer and more potent biologic than the anti-CD47 monoclonal antibodies and other SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. With IND clearance from the U.S. FDA and Taiwan FDA, HCB101 is currently being investigated in a multi-regional, multi-center, open-label, dose-finding clinical trial (NCT05892718) of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. Using HCB101 as the foundation, our multi-functional Fc-based designer biologics (FBDB™) platform pipeline includes other immune-modulating molecules targeting both adaptive and innate immunity to provide novel and efficacious treatments to patients suffering from difficult-to-treat cancers and other debilitating diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.
For more information, please visit HanchorBio or follow us on LinkedIn
Contact Information
Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com
Yuehua Cong
Chief Business Officer
yuehua_cong@hanchorbio.com
SOURCE: HanchorBio Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/811807/hanchorbio-to-present-at-the-esmo-immuno-oncology-2023-annual-congress
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Freedom Holding Corp. Founder Timur Turlov Announces Candidacy for FIDE Deputy President29.6.2026 15:25:00 CEST | Press release
ALMATY, KAZAKHSTAN AND NEW YORK, NY / ACCESS Newswire / June 29, 2026 / Timur Turlov, President of the Kazakhstan Chess Federation and founder and majority shareholder of Freedom Holding Corp., has announced his candidacy for the position of Deputy President of the International Chess Federation (FIDE). According to Turlov, his decision to run reflects the work the Kazakhstan Chess Federation has undertaken in recent years to develop, digitize and popularize chess across the country. "My goal is to bring more stability, balance and mutual understanding to FIDE. Freedom Holding Corp., as one of Central Asia's leading fintech groups, can help the federation become more digital and technology-driven," said Timur Turlov. He added that his candidacy also reflects Kazakhstan's growing role in the international chess community. "In this sense, I represent not only myself, but also Kazakhstan - a country that is increasingly seen internationally as a reliable partner, capable of building calm
Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting27.6.2026 01:40:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 26, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that all six director nominees proposed by management were elected as directors of the Company at its annual meeting of shareholders held via live video webcast today. Each director will hold office until the close of the next annual meeting of the Company's shareholders or until their successors are duly elected or appointed. The following are the voting results based on proxies received and a vote by online ballot: Director Number of Votes Percentage of Votes Votes For: Votes Withheld: Votes For: Votes Withheld: Jaime Guillen 9,351,125 220,821 97.69% 2.31% James V. Lawless 9,345,405 226,541 97.63% 2.37% Marc Murnaghan 9,355,472 216,474 97.74% 2.26% Marcela Paredes de Vásquez 9,383,074 188,872 98.03% 1.97% Catherine Fagnan 9,386,661 185,285 98.06% 1.94% Adarsh P. Mehta 9,394,433 177,513 98.15% 1.85% About Polaris Renewable Energy Inc. Polaris Ren
FINOS Announces Intent to Form OSERA, a Global Financial Services-Led Alliance for Open Source Supply-Chain Resiliency in the Era of AI26.6.2026 15:00:00 CEST | Press release
Spearheaded by Moderne and Piloted by FINOS Institutional Members, the Open Source Enterprise Resiliency Alliance Mutualizes Open Source 'Backpatching', Promotes Vendor-Neutral Industry-Wide Remediation Standards and Accelerates Evidence-Based, Compliant Open Source Consumption at Scale NEW YORK CITY, NY / ACCESS Newswire / June 26, 2026 / At the Open Source in Finance Forum, FINOS, the financial services arm of the Linux Foundation, announced its intent to form an Open Source Enterprise Resiliency Alliance (OSERA), a global, vendor-neutral, member-governed coalition to strengthen the industry's supply chain resiliency. OSERA will strengthen the open source components that underpin the sector by securing them through a vendor-neutral, upstream-aware approach and accelerating their compliant consumption at scale. The announcement follows a successful Member-only end-to-end pilot phase by Deutsche Bank, Goldman Sachs, Morgan Stanley, Royal Bank of Canada (RBC), and TD Bank Group, in whic
Hydrosat and Kazakhstan Gharysh Sapary Sign Agreement to Advance Satellite-Based Water Intelligence Across Kazakhstan and Central Asia25.6.2026 17:00:00 CEST | Press release
BRUSSELS, BE / ACCESS Newswire / June 25, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, and JSC "NC "Kazakhstan Gharysh Sapary" (JSC "NC "KGS"), Kazakhstan's national space company, announced the signing of a Joint Activity Agreement during a ceremony held in Brussels on 23 June 2026. The agreement establishes the framework for a national-scale program to digitize water resources management using satellite-based thermal analytics and AI, with the potential to expand across Central Asia. The agreement was signed as part of the state visit of the Head of State of the Republic of Kazakhstan to Belgium. During the visit, a number of strategic agreements were concluded to advance artificial intelligence, science, digital infrastructure, and space technologies, creating new opportunities for investment, joint research, technology deployment, and international cooperation. Representing Kazakhstan at the signing ceremonies were Deputy Prime
GA-ASI Adapts Ground Control Station to Fly MQ-9B25.6.2026 16:00:00 CEST | Press release
World Leader in UAS Invests in Upgrades That Ease MQ-9B Procurement SAN DIEGO, CA / ACCESS Newswire / June 25, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is working to adapt its Block 30 Ground Control Stations (GCS) to fly the company's newer model MQ-9B SkyGuardian® and SeaGuardian® Remotely Piloted Aircraft. When these upgrades are complete, they will enable current users of the Block 30 system, originally designed to fly the MQ-9A Reaper®, to keep that equipment and use it to operate the more capable aircraft. Current users include the U.S. Air Force, U.S. Marine Corps, the Italian Air Force, the French Air Force, the United Arab Emirates Armed Forces, the Spanish Air Force, and the Royal Netherlands Air Force. GA-ASI developed the MQ-9B through its own internal research and development. The upgraded new aircraft required a new and more powerful GCS. The ongoing work with the Block 30 GCS now means that prospective users with existing stocks of equipment wouldn't ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom